litlas
Log inCreate account

Michel Sadelain

Active 1990–2026

173
Papers
59,152
Citations
107
h-index
169
i10-index

Citations

Citations per year for Michel Sadelain1990: 1 citations1991: 6 citations1992: 3 citations1993: 3 citations1994: 8 citations1995: 18 citations1996: 24 citations1997: 24 citations1998: 22 citations1999: 27 citations2000: 42 citations2001: 80 citations2002: 112 citations2003: 116 citations2004: 156 citations2005: 125 citations2006: 100 citations2007: 122 citations2008: 116 citations2009: 158 citations2010: 268 citations2011: 289 citations2012: 308 citations2013: 494 citations2014: 382 citations2015: 631 citations2016: 732 citations2017: 848 citations2018: 1,085 citations2019: 2,613 citations2020: 3,194 citations2021: 3,307 citations2022: 2,669 citations2023: 2,530 citations2024: 3,728 citations2025: 2,221 citations2026: 101 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 7,473 citing papers, 33.3% of this breakdownChina: 3,248 citing papers, 14.5% of this breakdownGermany: 1,406 citing papers, 6.3% of this breakdownUnited Kingdom: 1,127 citing papers, 5% of this breakdownItaly: 813 citing papers, 3.6% of this breakdownFrance: 734 citing papers, 3.3% of this breakdownJapan: 569 citing papers, 2.5% of this breakdownCanada: 563 citing papers, 2.5% of this breakdownSpain: 509 citing papers, 2.3% of this breakdownAustralia: 500 citing papers, 2.2% of this breakdownSwitzerland: 485 citing papers, 2.2% of this breakdownNetherlands: 481 citing papers, 2.1% of this breakdown
0%33.3%Other 20.2%

Institutions

Fields

  • Medicine59.3%
  • Biochemistry, Genetics and Molecular Biology25.7%
  • Immunology and Microbiology9.3%
  • Neuroscience2.3%
  • Engineering1.9%
  • Materials Science0.5%
  • Other1%

Topics

  • CAR-T cell therapy research16.3%
  • Virus-based gene therapy research5.6%
  • Immune Cell Function and Interaction5.6%
  • Immunotherapy and Immune Responses5.2%
  • CRISPR and Genetic Engineering4%
  • Cancer Immunotherapy and Biomarkers3.5%
  • Other59.8%

Coauthors

All papers

Open in search
  1. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

    Authors: Luis A. Rojas, Zachary Sethna, Kevin C. Soares, Cristina Olcese, Nan Pang, Erin Patterson, Jayon Lihm, Nicholas Ceglia, Pablo Guasp, Alexander L. Chu, Rebecca Yu, Adrienne Kaya Chandra, Theresa Waters, Jennifer Jin Ruan, Masataka Amisaki, Abderezak Zebboudj, Zagaa Odgerel, George C. Payne, Evelyna Derhovanessian, Felicitas Müller, Ina Rhee, Mahesh Yadav, Anton Dobrin, Michel Sadelain, Marta Łuksza, Noah A. Cohen, Laura H. Tang, Olca Baştürk, Mithat Gönen, Seth S. Katz, Richard Kinh Gian, Andrew S. Epstein, Parisa Momtaz, Wungki Park, Ryan Sugarman, Anna M. Varghese, Elizabeth Won, Avni M. Desai, Alice C. Wei, Michael I. D’Angelica, T. Peter Kingham, Ira Mellman, Taha Merghoub, Jedd D. Wolchok, Uğur Şahin, Özlem Türeci, Benjamin D. Greenbaum, William R. Jarnagin, Jeffrey A. Drebin, Eileen M. O’Reilly, Vinod P. Balachandran - Nature 2023 cited by 1,350

  2. Senolytic CAR T cells reverse senescence-associated pathologies

    Authors: Corina Amor, Judith Feucht, Josef Leibold, Yu-Jui Ho, Changyu Zhu, Direna Alonso‐Curbelo, Jorge Mansilla‐Soto, Jacob A. Boyer, Xiang Li, Theodoros Giavridis, Amanda Kulick, Shauna L Houlihan, Ellinor I.B. Peerschke, Scott L. Friedman, Vladimir Ponomarev, Alessandra Piersigilli, Michel Sadelain, Scott W. Lowe - Nature 2020 cited by 1,079

  3. Chimeric Antigen Receptor Therapy

    Authors: Carl H. June, Michel Sadelain - New England Journal of Medicine 2018 cited by 2,280

  4. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy

    Authors: Emma Morris, Sattva S. Neelapu, Theodoros Giavridis, Michel Sadelain - Nature reviews. Immunology 2021 cited by 1,039

  5. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

    Authors: Jae H. Park, Isabelle Rivière, Mithat Gönen, Xiuyan Wang, Brigitte Sénéchal, Kevin J. Curran, Craig S. Sauter, Yongzeng Wang, Bianca Santomasso, Elena Mead, Mikhail Roshal, P. Maslak, Marco L. Davila, Renier J. Brentjens, Michel Sadelain - New England Journal of Medicine 2018 cited by 2,675

  6. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

    Authors: Justin Eyquem, Jorge Mansilla‐Soto, Theodoros Giavridis, Sjoukje J. C. van der Stegen, Mohamad Hamieh, Kristen Cunanan, Ashlesha Odak, Mithat Gönen, Michel Sadelain - Nature 2017 cited by 1,854

  7. Gene therapy comes of age

    Authors: Cynthia E. Dunbar, Katherine A. High, J. Keith Joung, Donald B. Kohn, Keiya Ozawa, Michel Sadelain - Science 2018 cited by 1,378

  8. CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

    Authors: Theodoros Giavridis, Sjoukje J. C. van der Stegen, Justin Eyquem, Mohamad Hamieh, Alessandra Piersigilli, Michel Sadelain - Nature Medicine 2018 cited by 1,262

  9. The Basic Principles of Chimeric Antigen Receptor Design

    Authors: Michel Sadelain, Renier J. Brentjens, Isabelle Rivière - Cancer Discovery 2013 cited by 1,498

  10. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

    Authors: Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière, Stephen B. Solomon, Valerie W. Rusch, Roisin E. O’Cearbhaill, Amy Zhu, Waseem Cheema, Navin K. Chintala, Elizabeth Halton, John Pineda, Rocío Pérez-Johnston, Kay See Tan, Bobby Daly, Jose A. Araujo Filho, Daniel Ngai, Erin McGee, A. Vincent, Claudia Diamonte, Jennifer L. Sauter, Shanu Modi, Devanjan Sikder, Brigitte Sénéchal, Xiuyan Wang, William D. Travis, Mithat Gönen, Charles M. Rudin, Renier J. Brentjens, David R. Jones, Michel Sadelain - Cancer Discovery 2021 cited by 560

  11. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling

    Authors: Stuart M. Chambers, Christopher A. Fasano, Eirini P. Papapetrou, Mark Tomishima, Michel Sadelain, Lorenz Studer - Nature Biotechnology 2009 cited by 3,674

  12. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

    Authors: Marco L. Davila, Isabelle Rivière, Xiuyan Wang, Shirley Bartido, Jae H. Park, Kevin J. Curran, Stephen S. Chung, Jolanta Stefanski, Oriana Bórquez-Ojeda, Malgorzata Olszewska, Jinrong Qu, Teresa Wasielewska, Qing He, Mitsú J. Fink, Himaly Shinglot, Maher Youssif, Mark Satter, Yongzeng Wang, James Hosey, Hilda Quintanilla, Elizabeth Halton, Yvette Bernal, Diana Bouhassira, Maria E. Arcila, Mithat Gönen, Gail J. Roboz, P. Maslak, Dan Douer, Mark G. Frattini, Sergio Giralt, Michel Sadelain, Renier J. Brentjens - Science Translational Medicine 2014 cited by 2,497

  13. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

    Authors: Mohamad Hamieh, Anton Dobrin, Annalisa Cabriolu, Sjoukje J. C. van der Stegen, Theodoros Giavridis, Jorge Mansilla‐Soto, Justin Eyquem, Zeguo Zhao, Benjamin M. Whitlock, Matthew M. Miele, Zhuoning Li, Kristen Cunanan, Morgan Huse, Ronald C. Hendrickson, Xiuyan Wang, Isabelle Rivière, Michel Sadelain - Nature 2019 cited by 665

  14. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

    Authors: Bianca Santomasso, Jae H. Park, Darin Salloum, Isabelle Rivière, Jessica Flynn, Elena Mead, Elizabeth Halton, Xiuyan Wang, Brigitte Sénéchal, Terence J. Purdon, Justin R. Cross, Hui Liu, Behroze Vachha, Xi Chen, Lisa M. DeAngelis, Daniel Li, Yvette Bernal, Mithat Gönen, Hans-Guido Wendel, Michel Sadelain, Renier J. Brentjens - Cancer Discovery 2018 cited by 924

  15. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

    Authors: Leonid Cherkassky, Aurore Morello, Jonathan Villena‐Vargas, Yang Feng, Dimiter S. Dimitrov, David R. Jones, Michel Sadelain, Prasad S. Adusumilli - Journal of Clinical Investigation 2016 cited by 1,063

  16. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

    Authors: Zeguo Zhao, Maud Condomines, Sjoukje J. C. van der Stegen, Fabiana Perna, Christopher C. Kloss, Gertrude Gunset, Jason Plotkin, Michel Sadelain - Cancer Cell 2015 cited by 838

  17. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

    Authors: Renier J. Brentjens, Marco L. Davila, Isabelle Rivière, Jae H. Park, Xiuyan Wang, Lindsay G. Cowell, Shirley Bartido, Jolanta Stefanski, Clare Taylor, Malgorzata Olszewska, Oriana Bórquez-Ojeda, Jinrong Qu, Teresa Wasielewska, Qing He, Yvette Bernal, Ivelise Rijo, Cyrus V. Hedvat, Rachel Kobos, Kevin J. Curran, Peter G. Steinherz, Joseph G. Jurcic, Todd Rosenblat, P. Maslak, Mark G. Frattini, Michel Sadelain - Science Translational Medicine 2013 cited by 2,077

  18. Therapeutic T cell engineering

    Authors: Michel Sadelain, Isabelle Rivière, Stanley R. Riddell - Nature 2017 cited by 898

  19. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

    Authors: Judith Feucht, Jie Sun, Justin Eyquem, Yu-Jui Ho, Zeguo Zhao, Josef Leibold, Anton Dobrin, Annalisa Cabriolu, Mohamad Hamieh, Michel Sadelain - Nature Medicine 2018 cited by 543

  20. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

    Authors: Melody Smith, Anqi Dai, Guido Ghilardi, Kimberly V. Amelsberg, Sean M. Devlin, Raymone Pajarillo, John Slingerland, Silvia Beghi, Pamela S. Herrera, Paul A. Giardina, Annelie Clurman, Emmanuel Agyemang Dwomoh, Gabriel K. Armijo, Antonio L. C. Gomes, Eric R. Littmann, Jonas Schlüter, Emily Fontana, Ying Taur, Jae H. Park, Maria Lia Palomba, Elizabeth Halton, Josel D. Ruiz, Tania Jain, Martina Pennisi, Aishat Olaide Afuye, Miguel‐Angel Perales, Craig W. Freyer, Alfred L. Garfall, Shannon Gier, Sunita D. Nasta, Daniel J. Landsburg, James N. Gerson, Jakub Svoboda, Justin R. Cross, Elise A. Chong, Sergio Giralt, Saar Gill, Isabelle Rivière, David L. Porter, Stephen J. Schuster, Michel Sadelain, Noelle V. Frey, Renier J. Brentjens, Carl H. June, Eric G. Pamer, Jonathan U. Peled, Andrea Facciabene, Marcel R.M. van den Brink, Marco Ruella - Nature Medicine 2022 cited by 309

  21. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

    Authors: John Maher, Renier J. Brentjens, Gertrude Gunset, Isabelle Rivière, Michel Sadelain - Nature Biotechnology 2002 cited by 1,019

  22. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction

    Authors: Corina Amor, Inés Fernández-Maestre, Saria Chowdhury, Yu-Jui Ho, Sandeep Nadella, Courtenay Graham, Sebastian E. Carrasco, Emmanuella Nnuji-John, Judith Feucht, Clemens Hinterleitner, Valentin J.A. Barthet, Jacob A. Boyer, Riccardo Mezzadra, Matthew Wereski, David A. Tuveson, Ross L. Levine, Lee W. Jones, Michel Sadelain, Scott W. Lowe - Nature Aging 2024 cited by 184

  23. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

    Authors: Katrin Mestermann, Theodoros Giavridis, Justus Weber, Julian Rydzek, Silke Frenz, Thomas Nerreter, Andreas Mades, Michel Sadelain, Hermann Einsele, Michael Hudecek - Science Translational Medicine 2019 cited by 503

  24. PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

    Authors: V D Fedorov, Maria Themeli, Michel Sadelain - Science Translational Medicine 2013 cited by 731